Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Investigating the value of abatacept in the treatment of rheumatoid arthritis: a systematic review of cost-effectiveness studies.

Athanasakis K, Petrakis I, Kyriopoulos J.

ISRN Rheumatol. 2013 May 30;2013:256871. doi: 10.1155/2013/256871. Print 2013.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

3.

Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.

Cimmino MA, Leardini G, Salaffi F, Intorcia M, Bellatreccia A, Dupont D, Beresniak A.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):633-41. Epub 2011 Aug 31.

PMID:
21813056
4.

Influence of tumor necrosis factor α in rheumatoid arthritis.

Kulp W, Corzillus M, Greiner W, Pientka L, Siebert U, von der Schulenburg JM, Wasem J.

GMS Health Technol Assess. 2005 Dec 21;1:Doc12.

5.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

6.

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Li T, Oster G.

J Rheumatol. 2008 Sep;35(9):1745-53. Epub 2008 Jul 15.

PMID:
18634164
7.

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, Maclean R, Dupont D.

Clin Rheumatol. 2009 Apr;28(4):403-12. doi: 10.1007/s10067-008-1060-4. Epub 2008 Dec 17.

PMID:
19089488
8.

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.

Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.

Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.

PMID:
19884622
9.
10.

Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.

Cortejoso-Fernández L, Romero-Jiménez MR, Pernía-López MS, Montoro-Álvarez M, Sanjurjo-Sáez M.

J Pharm Pharm Sci. 2012;15(1):46-51.

11.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

12.

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, Lühmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

13.

Abatacept for rheumatoid arthritis.

Maxwell L, Singh JA.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277. doi: 10.1002/14651858.CD007277.pub2. Review.

PMID:
19821401
14.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

15.

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, Smolen JS, Aletaha D.

Ann Rheum Dis. 2010 Jun;69(6):995-1003. doi: 10.1136/ard.2009.126714. Epub 2010 May 6. Review.

PMID:
20447950
16.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
17.

Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.

Massarotti EM.

Clin Ther. 2008 Mar;30(3):429-42. doi: 10.1016/j.clinthera.2008.03.002. Review.

PMID:
18405783
18.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

19.

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

Reynolds J, Shojania K, Marra CA.

Pharmacotherapy. 2007 Dec;27(12):1693-701. Review.

PMID:
18041889
20.

Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.

Rheumatology (Oxford). 2007 Aug;46(8):1345-54. Epub 2007 Jun 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk